Serum Levels of Brain-Derived Neurotrophic Factor and Cortisol to Sulfate of Dehydroepiandrosterone Molar Ratio Associated With Clinical Response to l-Theanine as Augmentation of Antipsychotic Therapy in Schizophrenia and Schizoaffective Disorder Patients

Miodownik, Chanoch; Maayan, Rachel; Ratner, Yaël; Lerner, Vladimir; Pintov, Leonid; Mar, Maria; Weizman, Abraham; Ritsner, Michael S.

doi:10.1097/wnf.0b013e318220d8c6

Cited by 27 publications

(25 citation statements)

References 58 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The studies were published from 2009 to 2015 and conducted in North America ( n = 3) [31,32,33], East Asia ( n = 2) [34,35], and the Middle East ( n = 1) [36]. Of the included six RCTs, only two studies [31,34] were performed under AC conditions and one [31] was under a two-arm control design, i.e., AC and PC.…”

Section: Resultsmentioning

confidence: 99%

“…The proportion of males was 68.9% ± 5.7%. Only two studies reported that the length of illness ranged from 9.3 ± 7.3 to 25.3 ± 9.6 years [34,36]. The mean antipsychotic daily dose in CPZ equivalent doses [37,38,39,40] varied from 258.9 ± 232.5 to 733.5 ± 432.5 mg.…”

Section: Resultsmentioning

confidence: 99%

“…Almost all studies except one [31] were carried out using exercise or physical training [32,34,35] or diet products [33,36]. One study [31] used cognitive training.…”

Section: Resultsmentioning

confidence: 99%

See 2 more Smart Citations

The Efficacy of Non-Pharmacological Interventions on Brain-Derived Neurotrophic Factor in Schizophrenia: A Systematic Review and Meta-Analysis

Sanada

Zorrilla

Iwata

et al. 2016

IJMS

View full text Add to dashboard Cite

Several studies have investigated the relationship between non-pharmacological interventions (NPIs) and peripheral brain-derived neurotrophic factor (BDNF) in schizophrenia patients. We conducted a systematic review and meta-analysis to review the efficacy of NPIs on peripheral serum and plasma BDNF in subjects with schizophrenia (including schizoaffective disorder). Meta-analyses were conducted to examine the effects of NPIs on blood BDNF levels by using the standardized mean differences (SMDs) between the intervention groups and controls. In total, six randomized controlled trials with 289 participants were included. Of them, five studies used exercise, physical training or diet products. One study used cognitive training. Overall, the BDNF levels in the NPI group increased significantly compared with the control groups (SMD = 0.95, 95% confidence interval (CI) = 0.07 to 1.83, p = 0.03). Subgroup analyses indicated beneficial effects of a non-exercise intervention on peripheral BDNF levels (SMD = 0.41, 95% CI = 0.08 to 0.74, p = 0.01). Meta-regression analyses showed that the completion rate influenced the variation in SMD (p = 0.01). Despite insufficient evidence to draw a conclusion, our results suggest that use of NPIs as adjunctive treatments, specifically non-exercise interventions, may affect positively serum or plasma BDNF in patients with schizophrenia.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

The Efficacy of Non-Pharmacological Interventions on Brain-Derived Neurotrophic Factor in Schizophrenia: A Systematic Review and Meta-Analysis

Sanada

Zorrilla

Iwata

et al. 2016

IJMS

View full text Add to dashboard Cite

show abstract

“…However, negative symptomatology, objective neurocognitive functioning, general functioning, quality of life and side effect prevalence did not differ in the groups. In terms of the mechanism of this supplement, circulating levels of neurochemical indicator brain-derived neurotrophic factor (BDNF) and cortisol-to-dehydroepiandrosterone sulphate (DHEAS)*100 molar ratio appear to be associated with the observed clinical improvements in schizophrenia symptoms, although the exact reason for this relationship is unclear [67]. Miodownik et al postulate that alterations in serum BDNF level and cortisol-to-DHEAS*100 molar ratio may mediate the beneficial effects of L-Theanine augmentation.…”

Section: Methodsmentioning

confidence: 99%

Nutritional interventions for the adjunctive treatment of schizophrenia: a brief review

Arroll¹,

Wilder²,

James³

2014

Nutr J

View full text Add to dashboard Cite

Schizophrenia is a chronic condition that impacts significantly not only on the individual and family, but the disorder also has wider consequences for society in terms of significant costs to the economy. This highly prevalent condition affects approximately 1% of the worldwide population, yet there are few therapeutic options. The predominant treatment strategy for schizophrenia is anti-psychotic medication (with or without additional talking therapy) even though this approach lacks efficacy in managing the negative symptoms of the condition, is not effective in one-third of the patient group and the side effects of the medication can be severe and debilitating. In recent years, a number of pathophysiological processes have been identified in groups of people with schizophrenia including oxidative stress, one-carbon metabolism and immune-mediated responses. A number of studies have shown that these altered physiological mechanisms can be ameliorated by nutritional interventions in some individuals with schizophrenia. This review briefly describes the aforementioned processes and outlines research that has investigated the utility of nutritional approaches as an adjunct to anti-psychotic medication including antioxidant and vitamin B supplementation, neuroprotective and anti-inflammatory nutrients and exclusion diets. Whilst none of these interventions provides a ‘one-size-fits-all’ therapeutic solution, we suggest that a personalised approach warrants research attention as there is growing agreement that schizophrenia is a spectrum disorder that develops from the interplay between environmental and genetic factors.Electronic supplementary materialThe online version of this article (doi:10.1186/1475-2891-13-91) contains supplementary material, which is available to authorized users.

show abstract

“…The proportion of males was 68.9% ± 5.7%. Only two studies reported that the length of illness ranged from 9.3 ± 7.3 to 25.3 ± 9.6 years [34,36]. The mean antipsychotic daily dose in CPZ equivalent doses [37][38][39][40] varied from 258.9 ± 232.5 to 733.5 ± 432.5 mg.…”

Section: Included Randomized Controlled Trials (Rcts)mentioning

confidence: 99%

The efficacy of non-pharmacological interventions on brain-derived neurotrophic factor in schizophrenia: a systematic review and meta-analysis

Sanada¹,

Zorrilla²,

Bermúdez-Ampudia³

et al. 2016

European Neuropsychopharmacology

View full text Add to dashboard Cite

Serum Levels of Brain-Derived Neurotrophic Factor and Cortisol to Sulfate of Dehydroepiandrosterone Molar Ratio Associated With Clinical Response to l-Theanine as Augmentation of Antipsychotic Therapy in Schizophrenia and Schizoaffective Disorder Patients

Abstract: These preliminary results indicate that circulating BDNF and cortisol-to-DHEAS*100 molar ratio may be involved in the beneficial clinical effects of L-theanine as augmentation of antipsychotic therapy in schizophrenia and schizoaffective disorder patients.

Cited by 27 publications

References 58 publications

The Efficacy of Non-Pharmacological Interventions on Brain-Derived Neurotrophic Factor in Schizophrenia: A Systematic Review and Meta-Analysis

The Efficacy of Non-Pharmacological Interventions on Brain-Derived Neurotrophic Factor in Schizophrenia: A Systematic Review and Meta-Analysis

Nutritional interventions for the adjunctive treatment of schizophrenia: a brief review

The efficacy of non-pharmacological interventions on brain-derived neurotrophic factor in schizophrenia: a systematic review and meta-analysis

Contact Info

Product

Resources

About